CONFERENCE PROGRAM

Thursday, January 9

3:30 p.m.-8:15 p.m. REGISTRATION

California Foyer

6:30 p.m.-7:30 p.m. WELCOME AND OPENING KEYNOTE

California Ballroom

6:30 p.m.-6:40 p.m. **Welcome**

Elaine R. Mardis, Nationwide Children's Hospital, Columbus, OH

6:40 p.m.-7:30 p.m. **Keynote address**

Genomic-phenomic data linkages to accelerate discovery in oncology:

Obstacles and opportunities

Deborah Schrag, Dana-Farber Cancer Institute, Boston, MA

7:30 p.m.-8:15 p.m. PANEL DISCUSSION

Amy P. Abernathy, U.S. Food and Drug Administration, Silver Spring, MD David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, NY

Elaine R. Mardis, Nationwide Children's Hospital, Columbus, OH Deborah Schrag, Dana-Farber Cancer Institute, Boston, MA

Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA

8:15 p.m.-10:00 p.m. OPENING RECEPTION

Garden Terrace

Friday, January 10

7:00 a.m.-8:00 a.m. BREAKFAST

Garden Terrace

8:00 a.m.-9:45 a.m. PLENARY SESSION 1: MACHINE LEARNING IN PRECISION ONCOLOGY

California Ballroom

Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

8:00 a.m.-8:25 a.m. The Treehouse Childhood Cancer Initiative

David Haussler, University of California Santa Cruz, Santa Cruz, CA

CONFERENCE PROGRAM

8:25 a.m.-8:50 a.m. **Drug-predictive computational evaluations** Benjamin Haibe-Kains, Princess Margaret Cancer Centre, Toronto, ON, Canada Clinical challenges in oncologic imaging: Al support from image analysis to 8:50 a.m.-9:15 a.m. integrated diagnostics Evis Sala, University of Cambridge, Cambridge, United Kingdom 9:15 a.m.-9:45 a.m. Panel discussion 9:45 a.m.-10:00 a.m. **BREAK** California Foyer 10:00 a.m.-11:45 a.m. **PLENARY SESSION 2: DATABASES AND EHRS** California Ballroom Session Chair: Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA 10:00 a.m.-10:25 a.m. EHR-derived data platforms to advance precision medicine Neal J. Meropol, Flatiron Health, New York, NY 10:25 a.m.-10:50 a.m. Count me in: Partnering with patients to accelerate the pace of discoveries Corrie Painter, Broad Institute of Harvard and MIT/CountMeIn, Cambridge, MA 10:50 a.m.-11:15 a.m. Making it easier to participate in research: A patient's perspective Liz Salmi, OpenNotes/Beth Israel Deaconess Medical Center, Boston, MA 11:15 a.m.-11:45 a.m. **Panel discussion POSTER SESSION / LUNCH** 12:00 p.m.-2:45 p.m. San Diego Ballroom and Garden Terrace PLENARY SESSION 3: PANEL DISCUSSION ON REAL-WORLD EVIDENCE 3:00 p.m.-4:45 p.m. **GENERATION, PAYMENT MODELS, AND ENDPOINTS** California Ballroom Session Moderator: Elaine R. Mardis, Nationwide Children's Hospital, Columbus, OH 3:00 p.m.-3:15 p.m. Finding the right patient, finding the right trial Lee Newcomer, Lee N. Newcomer Consulting, Wayzata, MN Building data and knowledge management systems to support precision medicine 3:15 p.m.-3:30 p.m. Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA Toward personalized health care in oncology 3:30 p.m.-3:45 p.m. Levi A. Garraway, Genentech, South San Francisco, CA (not eligible for CME credit) 3:45 p.m.-4:00 p.m. A platform approach to regulatory-grade RWE and outcomes validation Jonathan Hirsch, Syapse, San Francisco, CA (not eligible for CME credit)

4:00 p.m.-4:45 p.m. Panel discussion

(not eligible for CME credit)

4:45 p.m. **DINNER ON OWN**

Saturday, January 11

7:00 a.m.-8:00 a.m. BREAKFAST

Garden Terrace

8:00 a.m.-9:45 a.m. PLENARY SESSION 4: NOVEL DRUG DEVELOPMENT APPROACHES / DRUGGING

DIFFICULT TARGETS

California Ballroom

Session Chair: David M. Hyman, Memorial Sloan Kettering Cancer Center,

New York, NY

8:00 a.m.-8:25 a.m. Title to be announced

José Baselga, AstraZeneca, Gaithersburg, MD

(not eligible for CME credit)

8:25 a.m.-8:50 a.m. Title to be announced

Jeffrey A. Engelman, Novartis, Cambridge, MA

(not eligible for CME credit)

8:50 a.m.-9:15 a.m. Lessons learned from challenging drug targets

Levi A. Garraway, Genentech, South San Francisco, CA

(not eligible for CME credit)

9:15 a.m.-9:45 a.m. Panel discussion

(not eligible for CME credit)

9:45 a.m.-10:00 a.m. BREAK

California Foyer

10:00 a.m.-11:45 a.m. PLENARY SESSION 5: WHAT CONSTITUTES ADEQUATE SCREENING?

California Ballroom

Session Chair: Elaine R. Mardis, Nationwide Children's Hospital, Columbus, OH

10:00 a.m.-10:25 a.m. Title to be announced

Barry S. Taylor, Memorial Sloan Kettering Cancer Center, New York, NY

CONFERENCE PROGRAM

10:25 a.m.-10:50 a.m. Longitudinal single-cell DNA sequencing to reveal rare cancer cell populations and

genome-phenome states in tumors

Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, NY

10:50 a.m.-11:15 a.m. Biomarkers and translational oncology in immuno-oncology

Alexandra Snyder, Merck & Co., Rahway, NJ

(not eligible for CME credit)

11:15 a.m.-11:45 a.m. Panel discussion

12:00 p.m.-2:00 p.m. LUNCH

Garden Terrace

2:15 p.m.-4:00 p.m. PLENARY SESSION 6: UNIQUE CLINICAL TRIAL DESIGNS

California Ballroom

Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

2:15 p.m.-2:40 p.m. Title to be announced

J. Carl Barrett, AstraZeneca Pharmaceuticals, Waltham, MA

(not eligible for CME credit)

2:40 p.m.-3:05 p.m. The Drug Rediscovery protocol: Getting the most out of approved drugs

Emile E. Voest, Netherlands Cancer Institute, Amsterdam, Netherlands

3:05 p.m.-3:30 p.m. Title to be announced

David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, NY

3:30 p.m.-4:00 p.m. Panel discussion

4:00 p.m. DINNER ON OWN

Sunday, January 12

7:30 a.m.-8:30 a.m. BREAKFAST

Garden Terrace

8:30 a.m.-9:10 a.m. KEYNOTE LECTURE

California Ballroom

Session Chair: Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA

 $\label{large-scale} \textbf{Large-scale science in the private sector: The story of Grail and the early detection}$

of cancer

Richard D. Klausner, Lyell Immunopharma, South San Francisco, CA

9:15 a.m.-10:30 a.m. PLENARY SESSION 7: PANEL DISCUSSION ON PERSPECTIVES FROM BIOTECH

AND THE FINANCE SECTOR

California Ballroom

(not eligible for CME credit)

Moderators: J. Carl Barrett, AstraZeneca Pharmaceuticals, Waltham, MA, and **David M. Hyman,** Memorial Sloan Kettering Cancer Center, New York, NY

Philip Dreyfuss, Farallon Capital, San Francisco, CA

Thomas G. Roberts, Farallon Capital, San Francisco, CA

Caroline Savello, Color Genomics, Burlingame, CA

James Tananbaum, Foresite Capital, San Francisco, CA

10:30 a.m.-10:45 a.m. BREAK

California Foyer

10:45 a.m.-12:30 p.m. PLENARY SESSION 8: MRD / ADVANCED DIAGNOSTICS

California Ballroom

Session Chair: Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA

10:45 a.m.-11:10 a.m. Title to be announced

Eliezer M. Van Allen

11:10 a.m.-11:35 a.m. ctDNA as predictive biomarkers for response and toxicity with immunotherapy

Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

11:35 a.m.-12:00 p.m. Circulating tumor DNA analysis for personalized cancer monitoring and detection

Maximilian Diehn, Stanford University, Stanford, CA

12:00 p.m.-12:30 p.m. Panel discussion

12:30 p.m. CLOSING REMARKS AND DEPARTURE

California Ballroom